Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors

Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell receptor signaling and the irreversible BTK inhibitor ibrutinib can trigger dramatic clinical response...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthur, Rachael, Valle-Argos, Beatriz, Steele, Andrew J., Packham, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116064/
https://www.ncbi.nlm.nih.gov/pubmed/32924028
http://dx.doi.org/10.37349/etat.2020.00009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116064/
https://www.ncbi.nlm.nih.gov/pubmed/32924028
http://dx.doi.org/10.37349/etat.2020.00009

Ejemplares similares